Bayer Aktiengesellschaft

Bayer Animal Health Gmbh

Hubert Rast

Thomas Himmler

Werner Hallenbach

Martin Scheer

Herbert Voege

Alfons Grunenberg

Peter M Lange

Alfred Mitschker

Iris Heep

Arundev H Naik

Francisco Cabrera

Jordi Benet-Buchholz

Ernst Heinen

Matthias Kuhn

Reinhold Lohr

Oliver Vetter

The present invention relates to the trihydrate of pradofloxacin, to a process for its preparation and to antibacterial compositions comprising them.

Crystalline form of cyano-1-cyclopropy1-7-1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid

The present invention relates to a semi-hydrochloride of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinoline-carboxylic acid, to processes for its preparation and to antibacterial compositions comprising it. The semihydrochloride of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid can be described by the following formula:

Semi-hydrochloride of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid

Crystal modification B of 8-cyano-1-cyclopropyl-7-(1S,6S-2, 8-diazabicyclo&lsqb;4.3.0&rsqb;nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

Crystal modification C of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-&lsqb;4.3.0&rsqb;nonan-8-yl)-6-fluoro-1,4-dihyro-4-oxo-3-quinoline carboxylic

Crystal modification d of 8-cyano-1-cyclopropyl-7-(1s, 6s- 2,8-diazabicyclo-&lsqb;4.3.0&rsqb;nonan-8-yl)-6-fluoro-1,4- dihydro-4-oxo-3-quinolinecarboxylic acid

Crystal modification A of 8-cyano-1-cyclopropyl-7-(is,6s-2,8-diazabicyclo&lsqb;4.3.0&rsqb;nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

N-oxides as antibacterial agents

The present invention relates to the preparation of orally administrable formulations of quinolone- or naphthyridonecarboxylic acids by mixing quinolone- or naphthyridonecarboxylic acids as such or in the form of their water-soluble salts or derivatives, preferably in the form of their aqueous salt solutions, with embonic acid as such or in the form of its water-soluble salts or derivatives, preferably in the form of its aqueous salt solutions, in the presence of an excipient, optionally in the presence of auxiliaries, when using dry mixtures in the presence of water, and optionally converting the mixture obtained into further ready-to-use forms.

Orally administrable formulations of quinolone- or

Known antibacterial quinolonecarboxylic acid derivatives such as ciprofloxacin are administered to animals in their food in the form of weak cation exchangers loaded therewith. The taste is much improved and the animals accept the material more readily.

Preparation and use of ion exchange resins loaded with

A stabilized febantel formulation comprising febantel, a water-miscible organic diluent and an acid, base or buffer salt in an amount such that when diluted 1:10 with water the formulation has a pH value of about 3 to 5. The formulation is far more stable than in the absence of the acid, base or buffer salt.

Stabilized anthelmintic formulations

Growing community of inventors

Leverkusen, Germany

Hubert Rast